Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sucampo Pharmaceuticals SCMP

Healthcare Drug Manufacturers - Specialty & Generic
"Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development... see more

Recent & Breaking News (NDAQ:SCMP)

Sucampo to Present Results From Four Phase 3 Studies of AMITIZA(R) (lubiprostone) for Opioid-Induced Constipation at PAINWeek 2013

Globe Newswire September 4, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on BDE, ESV, SCMP and WSM

Accesswire September 4, 2013

Sucampo Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608

Globe Newswire August 7, 2013

Sucampo Receives $10 Million Milestone Payment from Takeda on First Sale of AMITIZA® (lubiprostone) for OIC in the US

Business Wire June 26, 2013

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferies 2013 Global Healthcare Conference

Business Wire May 30, 2013

Sucampo Pharmaceuticals Achieves Orphan Designation for Unoprostone Isopropyl for Treatment of Retinitis Pigmentosa by European Medicines Agency

Business Wire May 29, 2013

Sucampo Appoints Kei Tolliver to Board of Directors

Business Wire May 29, 2013

Sucampo to be Added to the NASDAQ Biotechnology Index

Business Wire May 15, 2013

Sucampo Pharmaceuticals to Host Update on AMITIZA® OIC Indication May 20th

Business Wire May 13, 2013

Sucampo Pharmaceuticals, Inc. Reports First Quarter 2013 Financial and Operating Results

Business Wire May 7, 2013

Sucampo Pharmaceuticals Announces First Quarter 2013 Results and Operating Highlights Teleconference and Webcast

Business Wire April 30, 2013

InvestorsGuru.com 47 Filtered Mid-Day Market Movers Recap

Investors Guru April 28, 2013

Free Research Reports on HSTM, IIVI, IRWD and SCMP Issued by the Bedford Report

Marketwired April 25, 2013

Sucampo Pharmaceuticals, Inc. And Revolution Lighting Technologies News (NASDAQ: SCMP) (NASDAQ: RVLT)

Accesswire April 24, 2013

FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain

Business Wire April 23, 2013

Sucampo Pharmaceuticals to Present at 20th Annual Future Leaders in the Biotech Industry Conference

Business Wire March 29, 2013

Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results

Business Wire March 13, 2013

Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Financial Results and Operating Highlights Teleconference and Webcast

Business Wire March 6, 2013

Sucampo Appoints Barbara A. Munder and Maureen E. O'Connell to Board of Directors

Business Wire March 1, 2013

Sucampo Announces Commercial Availability of RESCULA in U.S. Pharmacies

Business Wire February 19, 2013